According to DelveInsight, the market of Idiopathic Pulmonary Fibrosis in 7MM was found to be USD 1,510.4 Million in 2017, and is expected to increase during the course of the study period (2017–2030).
Among the 7MM, the United States accounts for the largest market size of IPF, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
The total prevalent population of IPF in the 7MM is expected to rise to 284,823 in 2030.
Key players in the Idiopathic Pulmonary Fibrosis market include MediciNova, FibroGen, Kadmon Corporation, Promedior, Galapagos NV and other.
For more details visit:
https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market#infographics
#LungDisease #Fibrosis #idiopathicpulmonaryfibrosis #pulmonaryfibrosis #ipf #lungs #lungfibrosis